NCT04511871View on ClinicalTrials.gov

A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 9, 2020

Primary Completion Date

October 24, 2024

Study Completion Date

March 29, 2025

Conditions
Solid TumorGastric CancerBreast CancerOvarian CancerSarcoma
Interventions
BIOLOGICAL

CCT303-406

Blood will be collected from subjects to isolate peripheral blood mononuclear cells for the production of CCT303-406. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion followed by a single dose of CCT303-406 via intravenous injection.

Trial Locations (1)

200032

Zhongshan Hospital Affiliated to Fudan University, Shanghai

All Listed Sponsors
collaborator

Shanghai Zhongshan Hospital

OTHER

lead

Shanghai PerHum Therapeutics Co., Ltd.

INDUSTRY